Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents
Diagnostics · 29.06.2025 · 15 (13) · 1658
DOI: 10.3390/diagnostics15131658 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 29.06.2025. Verfasst von Federica Andolfi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 224 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sarcoidosis is a multisystem inflammatory disease characterized by the immune-mediated formation of non-necrotizing epithelioid granulomas. Several commonly used medications can induce similar granulomatous reactions, known as drug-induced sarcoid-like reactions (DISRs), which closely mimic sarcoidosis. Despite their specificity in targeting molecular pathways, certain therapies—particularly targeted treatments—have increasingly been linked to DISRs.
Methods
This narrative review was based on a PubMed search using the terms “SARCOID LIKE REACTION” and “DRUG”. A cross-check was performed with “SARCOID” combined with each identified drug to identify misclassified cases. Drugs with limited evidence or weak pathogenetic plausibility were excluded, leaving only molecularly targeted therapies for consideration. Sources included case reports, case series, and reviews selected based on their clinical and scientific relevance, without any restrictions on time or language.
Results
In light of the available data, five main pharmacological groups were found to be associated to DISR: immune checkpoint inhibitors, TNF-α antagonists, BRAF inhibitors, monoclonal antibodies, and miscellaneous agents. Each group has distinct mechanisms of action and clinical indications, which likely affect the frequency, presentation, and timing of DISRs.
Conclusions
Diagnosing DISRs is challenging, and a structured approach is crucial for differentiating them from other conditions. To support clinicians, we propose a diagnostic algorithm to guide decision-making in suspected cases. Management should be individualized, as most DISRs either resolve spontaneously or improve after the discontinuation of the causative drug. Important factors influencing therapeutic decisions include the severity of the underlying disease, the availability of alternative treatments, and the extent of DISR manifestations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, 41121 Modena, Italy.
- Respiratory Disease Unit, University Hospital of Modena-Policlinico, 41124 Modena, Italy.
- Center for Rare Lung Disease, University Hospital of Modena-Policlinico, 41124 Modena, Italy.
ORCID-Profile: Dario Andrisani, Enrico Clini, Roberto Tonelli, Stefania Cerri
Zitieren
APA
Andolfi, F., Caffarri, L., Neviani, M., Rubini, S., Andrisani, D., Gozzi, F., Beghé, B., Clini, E., Tonelli, R., & Cerri, S. (2025). Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents. Diagnostics, 15(13), 1658. https://doi.org/10.3390/diagnostics15131658
Vancouver
Andolfi F, Caffarri L, Neviani M, Rubini S, Andrisani D, Gozzi F, et al. Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents. Diagnostics. 2025;15(13):1658. doi:10.3390/diagnostics15131658
BibTeX
@article{Andolfi2025,
author = {Andolfi, Federica and Caffarri, Luca and Neviani, Matilde and Rubini, Silvia and Andrisani, Dario and Gozzi, Filippo and Beghé, Bianca and Clini, Enrico and Tonelli, Roberto and Cerri, Stefania},
title = {Drug-Induced Sarcoid-like Reactions Associated to Targeted Therapies and Biologic Agents},
journal = {Diagnostics},
year = {2025},
volume = {15},
number = {13},
pages = {1658},
doi = {10.3390/diagnostics15131658}
}
EUVIMED